Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FA CD20 (Clusters of Differentiation 20) inhibitors
L01FA02 Ofatumumab
D09314 Ofatumumab (USAN/INN) <JP/US>
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG12 Ofatumumab
D09314 Ofatumumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Ofatumumab
D09314 Ofatumumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D09314 Ofatumumab (USAN/INN); Ofatumumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD20
D09314 Ofatumumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09314
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09314
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09314
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09314
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D09314
